The University of Chicago has long recognized the importance of clinician scientists capable of utilizing laboratory discoveries to evolve novel therapeutic approaches and using clinical observations to inform and shape basic investigations. The Career Development Program of the Chicago Breast Cancer SPORE is committed to identifying and mentoring investigators interested in translational breast cancer research. The program will primarily provide a tightly structured multidisciplinary mentoring for junior faculty with the greatest potential of developing independent programs in translational breast cancer research;however, exceptional senior faculty who demonstrate strong interest in developing a program of translational research in breast cancer may also be eligible. Investigators may come from clinical or basic science backgrounds, provided that their research aims are translational in nature. We will use a rigorous review process and work with department Chairs to identify and recruit the most talented and promising candidates who will undergo a rigorous and effective mentoring program. Programmatic leadership and individual mentoring will be provided by a multidisciplinary mentoring committee, which must include the necessary representation from the basic/population sciences, clinical sciences, and biostatistics so that all disciplines are represented for optimal mentoring of the awardee. These mentors are established cancer researchers and as members of the UCCRC have access to all the Cancer Center sponsored Cores. A unique aspect of this program is the inclusion of Dr. Eileen Dolan, an outstanding translational scientist who will serve as career mentor/coach for all junior faculty awardees. As Chairperson for the University of Chicago Committee on the Reappointment of Assistant Professors (COROAP) she knows what it takes to be promoted at the University of Chicago and will be available at regularly scheduled times to discuss career goals, activities, and aspirations for reappointment and eventual promotion with each Career Development awardee. The explicit expectation is that the awardees will utilize the resources made available to them for the development of independent research programs and acquisition of independent funding in breast cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA125183-04
Application #
7884644
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
4
Fiscal Year
2009
Total Cost
$98,611
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Guindalini, Rodrigo Santa; Zheng, Yonglan; Abe, Hiroyuki et al. (2018) Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers. Clin Cancer Res :
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Zheng, Yonglan; Walsh, Tom; Gulsuner, Suleyman et al. (2018) Inherited Breast Cancer in Nigerian Women. J Clin Oncol 36:2820-2825
Wang, Shengfeng; Ogundiran, Temidayo; Ademola, Adeyinka et al. (2018) Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiol Biomarkers Prev 27:636-643
Debiasi, Márcio; Polanczyk, Carisi A; Ziegelmann, Patrícia et al. (2018) Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol 8:156
Feng, Ye; Rhie, Suhn Kyong; Huo, Dezheng et al. (2017) Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiol Biomarkers Prev 26:1016-1026
Hamdi, Yosr; Soucy, Penny; Kuchenbaeker, Karoline B et al. (2017) Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat 161:117-134
Michailidou, Kyriaki (see original citation for additional authors) (2017) Association analysis identifies 65 new breast cancer risk loci. Nature 551:92-94
Rudin, Shoshana; Marable, Marcus; Huang, R Stephanie (2017) The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. Genomics Proteomics Bioinformatics 15:82-93
Geeleher, Paul; Huang, R Stephanie (2017) Exploring the Link between the Germline and Somatic Genome in Cancer. Cancer Discov 7:354-355

Showing the most recent 10 out of 203 publications